Skip to main content
. 2019 Aug 28;10:2058. doi: 10.3389/fimmu.2019.02058

Figure 1.

Figure 1

MP-IC change the expression of differentiation and activation markers in MDM. (A) Summarized methodological strategy used in this article is presented. (B) The MFI of markers associated with the differentiation of MDM: CD36, HLA-DR, CD16, CD16, CCR2, and SSC-A; MDM differentiated without [Unstimulated (Unstim), black dots] or with RMP (light gray dots) or RMP-IC (green dots) from patients with RA (n = 6) and HC (n = 6). (C) Representative histograms of markers associated with M1 polarization (from left to right: CD86, CD80, and TLR4) in MDM from patients with RA differentiated without (Unstim, black histograms) or with RMP (light gray histograms) or RMP-IC (green histograms); representative histograms of markers associated with M2 polarization (CD163 and CD209) in MDM from patients with SLE differentiated without (Unstim, black histograms) or with LMP (dark gray histograms) or LMP-IC (orange histograms). Blue histograms represent the FMO control for each marker. (D) Top, the MFI of markers associated with M1 and M2 polarizations in MDM from patients with RA (n = 6) and HC (n = 6) differentiated without (Unstim, black whisker box) or with RMP (light gray whisker box) or RMP-IC (green whisker box). Below, the MFI of markers associated with M1 and M2 polarizations in MDM from patients with SLE (n = 6) and HC (n = 6) differentiated without (Unstim, black whisker box) or with LMP (dark gray whisker box) or LMP-IC (orange whisker box). Comparisons among the groups were performed using ANOVA II and the Bonferroni post-hoc test.